|
1
|
Kumar CC: Genetic abnormalities and
challenges in the treatment of acute myeloid leukemia. Genes
Cancer. 2:95–107. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bennett JM, Catovsky D, Daniel MT, et al:
Proposed revised criteria for the classification of acute myeloid
leukemia. A report of the French-American-British Cooperative
Group. Ann Intern Med. 103:620–625. 1985. View Article : Google Scholar
|
|
3
|
Harris NL, Jaffe ES, Diebold J, et al:
World Health Organization classification of neoplastic diseases of
the hematopoietic and lymphoid tissues: report of the Clinical
Advisory Committee meeting - Airlie House, Virginia, November 1997.
J Clin Oncol. 17:3835–3849. 1999.
|
|
4
|
O’Donnell MR, Abboud CN, Altman J, et al:
Acute myeloid leukemia. J Natl Compr Cancer Netw. 10:984–1021.
2012.
|
|
5
|
Tallman MS, Nabhan C, Feusner JH, et al:
Acute promyelocytic leukemia: evolving therapeutic strategies.
Blood. 99:759–767. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Smith ML, Hills RK and Grimwade D:
Independent prognostic variables in acute myeloid leukaemia. Blood
Rev. 25:39–51. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wood WA and Lee SJ: Malignant hematologic
diseases in adolescents and young adults. Blood. 117:5803–5815.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shaffer BC, Gillet JP, Patel C, et al:
Drug resistance: still a daunting challenge to the successful
treatment of AML. Drug Resist Updat. 15:62–69. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Netto CD, Santos ES, Castro CP, et al:
(+/−)-3,4-Dihydroxy-8,9-methylenedioxypterocarpan and derivatives:
cytotoxic effect on human leukemia cell lines. Eur J Med Chem.
44:920–925. 2009.
|
|
10
|
Netto CD, da Silva AJ, Salustiano EJ, et
al: New pterocarpanquinones: synthesis, antineoplasic activity on
cultured human malignant cell lines and TNF-alpha modulation in
human PBMC cells. Bioorg Med Chem. 18:1610–1616. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Maia RC, Vasconcelos FC, de Sá Bacelar T,
et al: LQB-118, a pterocarpanquinone structurally related to
lapachol [2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone]: a
novel class of agent with high apoptotic effect in chronic myeloid
leukemia cells. Invest New Drugs. 29:1143–1155. 2011.
|
|
12
|
Salustiano EJ, Netto CD, Fernandes RF, et
al: Comparison of the cytotoxic effect of lapachol, alpha-lapachone
and pentacyclic 1,4-naphthoquinones on human leukemic cells. Invest
New Drugs. 28:139–144. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
de Sá Bacelar T, da Silva AJ, Costa PR, et
al: The pterocarpanquinone LQB 118 induces apoptosis in tumor cells
through the intrinsic pathway and the endoplasmic reticulum stress
pathway. Anticancer Drugs. 24:73–83. 2013.PubMed/NCBI
|
|
14
|
Adida C, Recher C, Raffoux E, et al:
Expression and prognostic significance of survivin in de novo acute
myeloid leukaemia. Br J Haematol. 111:196–203. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tamm I, Kornblau SM, Segall H, et al:
Expression and prognostic significance of IAP-family genes in human
cancers and myeloid leukemias. Clin Cancer Res. 6:1796–1803.
2000.PubMed/NCBI
|
|
16
|
Wuchter C, Leonid K, Ruppert V, et al:
Clinical significance of P-glycoprotein expression and function for
response to induction chemotherapy, relapse rate and overall
survival in acute leukemia. Leukemia. 14:1018–1024. 2000.
|
|
17
|
Nestal de Moraes G, Silva KL, Vasconcelos
FC, et al: Survivin overexpression correlates with an
apoptosis-resistant phenotype in chronic myeloid leukemia cells.
Oncol Rep. 25:1613–1619. 2011.PubMed/NCBI
|
|
18
|
Nestal de Moraes G, Souza PS, Costas FC,
et al: The interface between BCR-ABL-dependent and -independent
resistance signaling pathways in chronic myeloid leukemia. Leuk Res
Treatment. 2012:6717022012.PubMed/NCBI
|
|
19
|
Silva KL, de Souza PS, Nestal de Moraes G,
et al: XIAP and P-glycoprotein co-expression is related to imatinib
resistance in chronic myeloid leukemia cells. Leuk Res.
37:1350–1358. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Souza PS, Vasconcelos FC, De Souza Reis
FR, et al: P-glycoprotein and survivin simultaneously regulate
vincristine-induced apoptosis in chronic myeloid leukemia cells.
Int J Oncol. 39:925–933. 2011.
|
|
21
|
de Souza Reis FR, de Faria FC, Castro CP,
et al: The therapeutical potential of a novel pterocarpanquinone
LQB-118 to target inhibitor of apoptosis proteins in acute myeloid
leukemia cells. Anticancer Agents Med Chem. 13:341–351.
2013.PubMed/NCBI
|
|
22
|
Myatt SS and Lam EW: The emerging roles of
forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 7:847–859.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chapuis N, Park S, Leotoing L, et al: IκB
kinase overcomes PI3K/Akt and ERK/MAPK to control FoxO3a activity
in acute myeloid leukemia. Blood. 116:4240–4250. 2010.
|
|
24
|
Yang JY and Hung MC: A new fork for
clinical application: targeting forkhead transcription factors in
cancer. Clin Cancer Res. 15:752–757. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang X, Tang N, Hadden TJ, et al: Akt,
FoxO and regulation of apoptosis. Biochim Biophys Acta.
1813:1978–1986. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Leung TW, Lin SS, Tsang AC, et al:
Over-expression of FoxM1 stimulates cyclin B1 expression. FEBS
Lett. 507:59–66. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang IC, Chen YJ and Hughes D: Forkhead
box M1 regulates the transcriptional network of genes essential for
mitotic progression and genes encoding the SCF (Skp2-Cks1)
ubiquitin ligase. Mol Cell Biol. 25:10875–10894. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nakamura S, Hirano I, Okinaka K, et al:
The FOXM1 transcriptional factor promotes the proliferation of
leukemia cells through modulation of cell cycle progression in
acute myeloid leukemia. Carcinogenesis. 31:2012–2021. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wilson MS, Brosens JJ, Schwenen HD, et al:
FOXO and FOXM1 in cancer: the FOXO-FOXM1 axis shapes the outcome of
cancer chemotherapy. Curr Drug Targets. 12:1256–1266. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gallagher R, Collins S, Trujillo J, et al:
Characterization of the continuous, differentiating myeloid cell
line (HL-60) from a patient with acute promyelocytic leukemia.
Blood. 54:713–733. 1979.PubMed/NCBI
|
|
31
|
Lee KH, Chang MY, Ahn JI, et al:
Differential gene expression in retinoic acid-induced
differentiation of acute promyelocytic leukemia cells, NB4 and
HL-60 cells. Biochem Biophys Res Commun. 296:1125–1133. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ralph P, Harris PE, Punjabi CJ, et al:
Lymphokine inducing ‘terminal differentiation’ of the human
monoblast leukemia line U937: a role for gamma interferon. Blood.
62:1169–1175. 1983.
|
|
33
|
Cáceres-Cortés JR: Blastic leukaemias
(AML): a biologist’s view. Cell Biochem Biophys. 66:13–22.
2013.PubMed/NCBI
|
|
34
|
Lorin S, Hamaï A, Mehrpour M, et al:
Autophagy regulation and its role in cancer. Semin Cancer Biol.
23:361–379. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wrighton KH: Autophagy: kinase crosstalk
through beclin 1. Nat Rev Mol Cell Biol. 14:402–403. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sunters A, Fernández de Mattos S, Stahl M,
et al: FoxO3a transcriptional regulation of Bim controls apoptosis
in paclitaxel-treated breast cancer cell lines. J Biol Chem.
278:49795–49805. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kelly RJ, Lopez-Chavez A, Citrin D, et al:
Inhibitors of apoptosis proteins (IAPs) as potential molecular
targets for therapy of hematological malignancies. Curr Mol Med.
11:633–649. 2011. View Article : Google Scholar
|
|
38
|
Howlader N, Noone AM, Krapcho M, et al:
SEER Cancer Statistics Review, 1975–2010. National Cancer
Institute; Bethesda, MD: http://seer.cancer.gov/csr/1975_2010/,
based on November 2012 SEER data submission, posted to the SEER web
site. 2013
|
|
39
|
da Cunha EF Júnior, Pacienza-Lima W,
Ribeiro GA, et al: Effectiveness of the local or oral delivery of
the novel naphthop-terocarpanquinone LQB-118 against cutaneous
leishmaniasis. J Antimicrob Chemother. 66:1555–1559. 2011.
|
|
40
|
Ribeiro GA, Cunha-Júnior EF, Pinheiro RO,
et al: LQB-118, an orally active pterocarpanquinone, induces
selective oxidative stress and apoptosis in Leishmania amazonensis.
J Antimicrob Chemother. 68:789–799. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Van Der Heide LP, Hoekman MF and Smidt MP:
The ins and outs of FoxO shuttling: mechanisms of FoxO
translocation and transcriptional regulation. Biochem J.
380:297–309. 2004.PubMed/NCBI
|
|
42
|
Santamaría CM, Chillón MC, García-Sanz R,
et al: High FoxO3a expression is associated with a poorer prognosis
in AML with normal cytogenetics. Leuk Res. 33:1706–1709.
2009.PubMed/NCBI
|
|
43
|
Sykes SM, Lane SW, Bullinger L, et al:
AKT/FOXO signaling enforces reversible differentiation blockade in
myeloid leukemia. Cell. 146:697–708. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kornblau SM, Singh N, Qiu Y, et al: Highly
phosphorylated FOXO3A is an adverse prognostic factor in acute
myeloid leukemia. Clin Cancer Res. 16:1865–1874. 2010. View Article : Google Scholar
|
|
45
|
Sakoe Y, Sakoe K, Kirito K, et al: FOXO3A
as a key molecule for all-trans retinoic acid-induced granulocytic
differentiation and apoptosis in acutepromyelocytic leukemia.
Blood. 115:3787–3795. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Thépot S, Lainey E, Cluzeau T, et al:
Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia.
Cell Cycle. 10:2323–2330. 2011.PubMed/NCBI
|
|
47
|
Kelly KR, Nawrocki ST, Espitia CM, et al:
Targeting Aurora A kinase activity with the investigational agent
alisertib increases the efficacy of cytarabine through a
FOXO-dependent mechanism. Int J Cancer. 131:2693–2703. 2012.
View Article : Google Scholar
|
|
48
|
Scheijen B, Ngo HT, Kang H, et al: FLT3
receptors with internal tandem duplications promote cell viability
and proliferation by signaling through Foxo proteins. Oncogene.
23:3338–3349. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhao F and Lam EW: Role of the forkhead
transcription factor FOXO-FOXM1 axis in cancer and drug resistance.
Front Med. 6:376–380. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Koo CY, Muir KW and Lam EW: FOXM1: from
cancer initiation to progression and treatment. Biochim Biophys
Acta. 1819:28–37. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhang X, Zeng J, Zhou M, et al: The tumor
suppressive role of miRNA-370 by targeting FoxM1 in acute myeloid
leukemia. Mol Cancer. 11:562012. View Article : Google Scholar : PubMed/NCBI
|
